REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$688.87|
|52 Week High||US$754.67|
|52 Week Low||US$538.01|
|1 Month Change||18.64%|
|3 Month Change||15.70%|
|1 Year Change||20.69%|
|3 Year Change||143.48%|
|5 Year Change||46.58%|
|Change since IPO||3,160.92%|
Recent News & Updates
Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition
The FDA has approved Dupixent, developed by Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) (GCVRX), for adults with prurigo nodularis, a chronic, inflammatory skin condition. The subcutaneously administered treatment is already indicated in the U.S. for conditions including atopic dermatitis and asthma, and the prurigo nodularis is the second skin condition the drug is greenlighted in the U.S. The decision is based on data from two Phase 3 trials, PRIME and PRIME2, in which 60% and 58% of Dupixent-treated patients witnessed a clinically meaningful decline in itch at 24 weeks from the baseline compared to 18% and 20% for placebo, as the primary endpoint. “Dupixent has the potential to transform the standard-of-care for prurigo nodularis patients by alleviating the key hallmarks of the disease, such as reducing itch and achieving clearer skin,” remarked Naimish Patel, Head of Global Development, Immunology and Inflammation at Sanofi (SNY). During Q2 2022, Dupixent added €1.96B in sales for Sanofi (SNY) with ~43% YoY growth.
|REGN||US Biotechs||US Market|
Return vs Industry: REGN exceeded the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: REGN exceeded the US Market which returned -23.2% over the past year.
|REGN Average Weekly Movement||6.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: REGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: REGN's weekly volatility (7%) has been stable over the past year.
About the Company
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
|REGN fundamental statistics|
Is REGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|REGN income statement (TTM)|
|Cost of Revenue||US$5.23b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||53.19|
|Net Profit Margin||39.97%|
How did REGN perform over the long term?See historical performance and comparison